Daiichi Sankyo exec on purposeful data collection
Daiichi Sankyo’s VP of digital excellence, Dr Patrick Markt-Niederreiter , has outlined how the pharma company makes ‘very conscious’ decisions…
All articles by Phalguni Deswal
Phalguni Deswal
@Phalguni_GD
Phalguni Deswal is reporter in the healthcare and pharmaceutical sector. With a background in medicine, Phalguni has experience working in the Indian healthcare sector. Phalguni is interested in metabolic drug therapies, digital health technologies, and drug development.
-
-
Veeva Commercial Summit: Increased investment in medical affairs by pharma companies
Pharmaceutical companies are always looking to increase the efficiency of clinical trials, and now many of these companies are looking…
-
Intelligent gears up for FDA approval of fingerprint drug detection device
US based company Intelligent Bio Solutions has released “strong initial results” from a pharmacokinetic (PK) study and is one step…
-
Syros stock craters after lead cancer therapy flops in Phase III trial
Syros Pharmaceuticals’ stock has declined sharply for the second time in the past three months as a Phase III trial…
-
Paratek’s antibiotic succeeds in Phase IIb lung disease trial
Boston-based Paratek Pharmaceuticals has released positive topline data from a Phase IIb trial evaluating its oral antibiotic Nuzyra (omadacycline) in…
-
AstraZeneca and Amgen’s Tezspire succeeds in Phase III nasal polyps trial
AstraZeneca and Amgen have released topline data from a Phase III trial of its inflammatory therapy, Tezspire (tezepelumab) in patients…
-
Castle boasts melanoma test’s capacity to reduce unnecessary testing
Castle Biosciences has released data from a multi-centre DECIDE study showing the impact of integrating its DecisionDx-Melanoma test results into…
-
Intra-Cellular bolsters Caplyta data with another Phase III win
Having raised the full-year sales guidance for Caplyta (lumateperone) a week ago, Intra-Cellular Therapeutics has reported positive topline data from…
-
Allurion boasts over 17% weight loss with swallowable balloon device
Allurion Technologies has presented data from two studies showing the efficacy of its swallowable gastric balloon in causing significant weight…
-
Biofrontera stock climbs as drug-device succeeds in Phase III skin cancer trial
US-based company Biofrontera has announced topline results from a Phase III trial evaluating its drug-device therapy, Ameluz gel and photodynamic…